Soumya Chakravarty, MD, PhD, FACP, FACR, senior director, strategic lead rheumatology therapeutic area, Johnson & Johnson Innovative Medicine, highlights the APEX study’s findings that Tremfya (guselkumab) is the first IL-23 […]
The post Shaping First-Line Therapy Decisions in PsA first appeared on Blackandmed .
